Reports Q4 revenue $1.83B, consensus $1.76B. "We closed out the fourth quarter strong, driven by the solid execution of our team and meaningful innovation in our portfolio – all against a backdrop of continued recovery post-pandemic," said Bryan Hanson, chairman, president and CEO of Zimmer Biomet. "As we enter 2023, we expect macro pressures to continue, but also to stabilize, setting up ZB to achieve attractive growth and mark another key milestone in our transformation journey. We remain committed to building out our portfolio, delivering on our mission and creating value for all of our stakeholders."
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ZBH:
- Zimmer Biomet Announces Fourth Quarter and Full-Year 2022 Financial Results
- Increasing Medical Issues Bode Well for Zimmer Biomet Stock (NYSE:ZBH)
- Zimmer Biomet upgraded to Outperform from Sector Perform at RBC Capital
- Zimmer Biomet price target raised to $130 from $120 at Piper Sandler
- Zimmer Biomet to Acquire Embody, Inc.